title: [Pharmacokinetic and clinical studies of cefdinir in pediatric field].
abstract: Cefdinir (CFDN) was evaluated for its efficacy and safety. The following results were obtained. 1. Pharmacokinetic study: CFDN was evaluated pharmacokinetically in 4 male children aged 9 to 13. CFDN was given orally to 3 children at a dose of 3 mg/kg. Peak plasma levels of 0.71 microgram/ml, 0.78 microgram/ml and 0.45 microgram/ml were attained in the 3 children, respectively, at 4 hours after dosing. Half-lives of CFDN in serum were 1.78 hours, 1.48 hours and 2.23 hours, respectively. The 12-hour urinary recovery rates of CFDN were 17.4%, 28.1% and 6.2%. When CFDN was given orally to the remaining child at a dose of 6 mg/kg, the peak plasma level was attained at 4 hours after dosing with a level of 1.16 micrograms/ml. T 1/2 was 1.78 hours. The 12-hour urinary recovery rate of CFDN was 15.0%. 2. Clinical study: CFDN 5 percent fine granules were given to 26 patients with infections; 2 with pneumonia, 4 with acute bronchitis, 1 with chronic bronchitis, 12 with pharyngitis, 4 with scarlet fever, 1 with otitis media and 2 with skin and soft tissue infections. Therapeutic responses were "excellent" in 15, "good" in 8, "fair" in 1 and "poor" in 2, with an efficacy rate of 88.5%. 3. Adverse reactions: As for adverse reactions, diarrhea was noted in 1 patient. It was concluded that CFDN is a useful drug for the treatment of the bacterial infections in pediatrics.
authors.affiliation: Department of Pediatrics, Sapporo City General Hospital.
authors.forename: N
authors.initials: N
authors.lastname: Fukushima
authors.forename: Y
authors.initials: Y
authors.lastname: Wagatsuma
authors.forename: A
authors.initials: A
authors.lastname: Takase
authors.forename: A
authors.initials: A
authors.lastname: Ishikawa
authors.forename: S
authors.initials: S
authors.lastname: Takahashi
mesh_terms: D000284:Administration, Oral; D000293:Adolescent; D000367:Age Factors; D001424:Bacterial Infections / Q000188:drug therapy* / Q000378:metabolism; D001991:Bronchitis / Q000188:drug therapy / Q000378:metabolism; D000077525:Cefdinir; D002511:Cephalosporins / Q000493:pharmacokinetics / Q000627:therapeutic use*; D002648:Child; D004341:Drug Evaluation; D006801:Humans; D008297:Male; D010612:Pharyngitis / Q000188:drug therapy / Q000378:metabolism
chemical_list: D002511:Cephalosporins; D000077525:Cefdinir